טוען...
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-opti...
שמור ב:
| הוצא לאור ב: | Chin J Cancer |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124233/ https://ncbi.nlm.nih.gov/pubmed/27887628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0162-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|